The Limited Times

Now you can see non-English news...

The prescription of biosimilars is leveling off in France

2022-07-06T16:53:22.032Z

About 30% less expensive than the original molecules, they represent a significant pool of savings. This will be one of the important issues for the new Minister of Health when closing the Social Security budget: how to promote the increase in the penetration of biosimilars (generic versions of biological drugs) in France in order to generate more savings. Penetration stagnated at 32%, with significant differences between the hospital (nearly 90%) and the city (23%), and depending on the molecu



This will be one of the important issues for the new Minister of Health when closing the Social Security budget: how to promote the increase in the penetration of biosimilars (generic versions of biological drugs) in France in order to generate more savings.

Penetration stagnated at 32%, with significant differences between the hospital (nearly 90%) and the city (23%), and depending on the molecules (less than 20% for insulin).

We are far from the target of 80% which had been set in 2018 by the former Minister of Health, Agnès Buzyn, and from the European average of 55%.

Because the list of biosimilar drugs available in France is still limited.

They are only 16, of which 9 are prescribed mainly in town.

Out of a total market of biological drugs of 4 billion euros, only a third is biosimilarizable (1.4 billion).

But the stakes are high.

Because they are around 30% cheaper, biosimilars represent an important pool…

This article is for subscribers only.

You have 71% left to discover.

Cultivating your freedom is cultivating your curiosity.

Keep reading your article for €0.99 for the first month

I ENJOY IT

Already subscribed?

Login

Source: lefigaro

All business articles on 2022-07-06

You may like

Trends 24h

Business 2022-08-16T12:12:28.521Z

Latest

© Communities 2019 - Privacy